29.03.2018 • NewsDede WillamsIndorama VenturesPET

Creditors to Buy M&G’s Texas PET Plant

Creditors to Buy M&G’s Texas PET Plant (c) George Clerk/Getty Images
Creditors to Buy M&G’s Texas PET Plant (c) George Clerk/Getty Images

Creditors of insolvent Italian plastics producer M&G Group (formerly Mossi & Ghisolfi) have teamed up to buy the mammoth PTA and PET plant the company’s subsidiary M&G Polymers USA was building at Corpus Christi, Texas, before it ran into problems and out of money.

The buyers, Thailand-based global PET market leader Indorama Ventures, Taiwan’s Far Eastern New Century Corporation (FENC) and Mexico’s Alpek, have formed a joint venture, CC Polymers, to take over the insolvent group’s remaining asset. The deal, subject to approval by a US bankruptcy court in the state of Delaware and applicable governmental authorities, includes related intellectual property.

The consortium has launched a binding bid of $1.1 billion in cash and other capital contributions to buy the complex, which is capable of producing 1.3m t/y of PTA and 1.1m t/y of PET and expected to be the world’s largest single-line vertically integrated PTA-PET production line and the largest PTA plant in the Americas. 

Each of the three buyers will have the right to take a third of the PTA and PET produced at Corpus Christi. A timeline for completion of the project – originally due on stream in 2016 – will be announced at a later date. Each of the companies will independently procure its own raw materials as well as independently selling and distributing its share of the output.

Indorama, reportedly M&G’s largest unsecured creditor, is believed to be owed  $56.6million. The Thai group recently acquired the 550,000 t/y PET plant of M&G Polimeros Brasil for an undisclosed sum. The facility is Brazil’s biggest. Far Eastern has paid $3.5 million to acquire M&G’s 360,000 t/y PET plant at Apple Grove, West Virginia, while Alpek has pledged to provide up to $60m in secured financing to support M&G’s Mexican operations pending approval of a restructuring plan.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Free Virtual Event

ProteiNext 2025

ProteiNext 2025

ProteiNext is an annual symposium that offers a platform for sharing insights on protein analysis